Format

Send to

Choose Destination
Breast Cancer Res. 2019 Jun 13;21(1):72. doi: 10.1186/s13058-019-1156-6.

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.

Author information

1
Yale University, School of Medicine, New Haven, CT, USA. david.rimm@yale.edu.
2
Department of Pathology, Yale Pathology Tissue Services, Yale University School of Medicine, 310 Cedar St. BML 116, PO Box 208023, New Haven, CT, 06520-8023, USA. david.rimm@yale.edu.
3
Texas A&M, College Station, TX, USA.
4
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
5
Mayo Clinic, Rochester, MN, USA.
6
University of Nebraska Medical Center, Omaha, NE, USA.
7
Fox Chase Cancer Center, Philadelphia, PA, USA.
8
Yale University, School of Medicine, New Haven, CT, USA.
9
VA Connecticut HealthCare System, West Haven, CT, USA.
10
University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
11
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associated with a better outcome. Two large studies have been done assessing immune cell PD-L1 expression in lung cancer. Here, we reanalyze one of those studies, to show that, even with an easier scoring method, there is still only poor agreement between assays and pathologist for immune cell PD-L1 expression.

KEYWORDS:

Atezolizumab; Immunohistochemistry; Non-small cell lung cancer; PD-L1; Triple-negative breast cancer

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center